BallowM.. Safety of IGIV therapy and infusion-related adverse events.Immunol Res.2007; 38(1-3): 122–132.
2.
StevensonK.B., HannahE.L., LowderC.A.. Epidemiology of hemodialysis vascular access infections from longitudinal infection surveillance data: predicting the impact of NKF-DOQI clinical practice guidelines for vascular access.Am J Kidney Dis.2002; 39(3): 549–555.
3.
Saeed AbdulrahmanI., Al-MueiloS.H., BokharyH.A., LadipoG.O., Al-RubaishA.. A prospective study of hemodialysis access-related bacterial infections.J Infect Chemother.2002; 8(3): 242–246.
MandayamS., AhujaT.S.. Dialyzing a patient with human immunodeficiency virus infection: what a nephrologist needs to know.Am J Nephrol.2004; 24(5): 511–521.
